Brought to you by 
Novartis looks to Intercell to help build vaccine pipeline; deal modified after strategic M&As by partners; terminated
26 Jun 2019
Executive Summary
Novartis has acquired the exclusive option to develop, manufacture, and sell Intercell AG's existing and future vaccine candidates for bacterial infections. The big pharma also gets an exclusive license to the Austrian biotech's IC31 technology for flu vaccines.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novartis looks to Intercell to help build vaccine pipeline; deal modified after strategic M&As by partners; terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice